Sputnik V (Gam-COVID-Vac)

• rAd26 & rAd5 vectored, full-length SARS-CoV-2 spike

• Regulatory approval in 50* countries, but few independent studies on immunogenicity or VE

• Phase III interim results reported (Gamaleya) VE (Sx) 91.6%

• Sputnik Light (Single dose rAd26) 78.6%

• Independent assessment of VE (St. Petersburg) 2

---

1 Logunov et al., Lancet Feb 20, 2021, PMID: 33545094; 

N = 602 (HCW Cohort)

- 100% developed Spike binding antibodies 21 days after 2nd dose.

Use of the Sputnik V vaccine in Argentina: Evaluation of the humor response to tax nation. Partial report January - March 2021
Previously infected HCW generate more potent *neutralizing* Abs after first vaccine dose

RBD binding *per se* does not appear to account for differences in neutralizing potency at this time point.

- 7 breakthrough cases during HCW longitudinal study (~1.2%, no CI)
- Mild COVID-19, no hospitalizations

<table>
<thead>
<tr>
<th>Anti-RBD titers in breakthrough Infections</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCW1</td>
</tr>
<tr>
<td>HCW2</td>
</tr>
<tr>
<td>HCW3</td>
</tr>
<tr>
<td>HCW4</td>
</tr>
<tr>
<td>HCW5</td>
</tr>
<tr>
<td>HCW6</td>
</tr>
<tr>
<td>HCW7</td>
</tr>
</tbody>
</table>
Neutralizing activity against SARS-CoV-2 variant spikes may decay at different rates?


Unpublished Data
Opinion on CoP

- Is live virus neutralization necessarily the gold standard (virus stock QC not standardized)
- Target cell type dependence
- Does one metric have sufficient power (ratio of metrics; binding/NT50)
- Delta variant and viral load: implications for neutralization assay